Ferrous iron formation following the co-aggregation of ferric iron and the Alzheimer's disease peptide β-amyloid (1–42)
For decades, a link between increased levels of iron and areas of Alzheimer’s disease (AD) pathology has been recognized, including AD lesions comprised of the peptide b-amyloid (Ab). Despite many observations of this association, the relationship between Ab and iron is poorly understood. Using X-ray microspectroscopy, X-ray absorption spectroscopy, electron microscopy and spectrophotometric iron(II) quantification techniques, we examine the interaction between Ab(1–42) and synthetic iron(III), reminiscent of ferric iron stores in the brain. We report Ab to be capable of accumulating iron(III) within amyloid aggregates, with this process resulting in Ab-mediated reduction of iron(III) to a redox-active iron(II) phase. Additionally, we show that the presence of aluminium increases the reductive capacity of Ab, enabling the redox cycling of the iron. These results demonstrate the ability of Ab to accumulate iron, offering an explanation for previously observed local increases in iron concentration associated with AD lesions. Furthermore, the ability of iron to form redox-active iron phases from ferric precursors provides an origin both for the redox-active iron previously witnessed in AD tissue, and the increased levels of oxidative stress characteristic of AD. These interactions between Ab and iron deliver valuable insights into the process of AD progression, which may ultimately provide targets for disease therapies.